Ani Pharmaceuticals (ANIP) Receivables - Other (2014 - 2022)
Ani Pharmaceuticals' (ANIP) quarterly Receivables - Other came in at $5.0 million in Q4 2022, down 37.5% quarter-over-quarter from $8.0 million in Q1 2014.
Powered by 
Analysis
Ani Pharmaceuticals (ANIP) Receivables - Other (2014 - 2022) Analysis & Trends
Ani Pharmaceuticals has disclosed Receivables - Other across 2 years of filings, most recently posting $5.0 million for Q4 2022.
- In Q4 2022, Receivables - Other changed N/A year-over-year to $5.0 million; the TTM figure through Dec 2022 stood at $5.0 million (changed N/A YoY), while the FY2022 annual figure was $5.0 million, changed N/A from the prior year.
- Receivables - Other came in at $5.0 million for Q4 2022 at Ani Pharmaceuticals, down from $8.0 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $5.0 million in Q4 2022 to a low of $5.0 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - |